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Abstract: Sleep and Klotho have both been closely related to the ageing process, both playing a
substantial role in the endocrine and immune systems and, thereby, in oxidative stress and chronic
inflammation. However, there are no studies elucidating the relationship between sleep and Klotho.
Therefore, this study investigated the association of sleep quantity and quality with the shed form of
the α-Klotho gene (S-Klotho plasma levels) in sedentary middle-aged adults. A total of 74 volunteers
(52.7% women; aged 53.7 ± 5.1) were recruited for the present study. Objective sleep quality
parameters (total sleep time (TST), wake after sleep onset (WASO), and sleep efficiency (SE)) were
determined using a wrist-worn accelerometer over seven consecutive days, and the subjective sleep
quality was assessed by the Pittsburgh Sleep Quality Index (PSQI; higher scores indicate worse sleep
quality). The S-Klotho plasma levels were measured in the ethylenediaminetetraacetic acid plasma
using a solid-phase sandwich enzyme-linked immunosorbent assay. Objective sleep parameters
were associated with the S-Klotho plasma levels only after including the age, fat mass percentage,
and lean mass index as covariates. A direct relationship was observed between the subjective sleep
quality (inverse of PSQI scores) and the S-Klotho plasma levels in sedentary middle-aged adults.
Improving sleep quantity and quality could be considered an anti-aging therapeutic approach for
the prevention, slowing, and even reversal of the physiological decline and degenerative pathologies
that are certainly related to the aging process.
Keywords: successful ageing; inflammation; oxidative stress; accelerometry
1. Introduction
The increasing population ageing occurring worldwide, with the subsequent upsurge in
vulnerability to morbidity and age-related diseases among adults, has certainly become one of
the most significant global clinical and economic burdens for health systems and all aspects of society.
According to the Global Burden of Disease Study 2017 [1], 51.3% of all burdens among adults were
identified as age-related diseases, mostly including non-communicable diseases such as neoplasms,
cardiovascular diseases, chronic respiratory diseases, diabetes and kidney diseases, digestive diseases,
and neurological disorders among others [2]. In response to this remarkable demographic transition,
the World Health Organization developed a global strategy and action plan on ageing and health
in 2017 with goals and strategic objectives focusing on health system alignment to the needs of
Antioxidants 2020, 9, 738; doi:10.3390/antiox9080738 www.mdpi.com/journal/antioxidants
Antioxidants 2020, 9, 738 2 of 13
the older population and the enhancement of measurement, monitoring, and research to support
healthy ageing [3,4].
In this context, the elucidation of aging mechanisms by advances in medicine and research has led
to the emergence of anti-aging medicine, a growing field of research and clinical practice focused on
the prevention, slowing, and even reversal of the physiological decline and degenerative pathologies
related to the aging process [5–9]. The approaches of anti-aging medicine include, among others,
calorie restriction mimetics, hormonal replacement, and gut microbiota and vitamin D interventions [5].
In this field of research, sleep could be considered a substantial key element involved in the restoration
and preservation of multiple physiological systems, including the endocrine function and metabolism,
immune response, and general brain metabolism [10–12]. Indeed, sleep deprivation has been closely
related to energy imbalance [13,14], adverse hormonal changes [15], gut microbiota alterations [16],
and vitamin D deficiency [17], all involved in the mechanisms of action of anti-aging medicine
interventions. Accordingly, gathered evidence has also widely shown that sleep disturbances certainly
lead to a vast number of age-related diseases [18], including obesity [19,20], cardiovascular disease [21],
type II diabetes mellitus [22,23], chronic kidney disease [24], and psychiatric disorders [25].
Similarly, the Klotho gene family has been established as an “aging-suppressor” factor that
accelerates aging when disrupted and extends life span when overexpressed through a wide variety
of mechanisms [26–30]. Specifically, evidence suggest that α-Klotho—a single-pass transmembrane
glycoprotein encoded by the Klotho gene and mainly expressed in the kidneys and brain choroid
plexus—modulates the insulin-like growth factor and Wnt signaling pathways; inhibits oxidative stress;
and regulates the metabolism of phosphate, calcium, and vitamin D in humans [28,29]. Within the three
identified α-Klotho protein types [31], its secreted (or soluble) form (S-Klotho)—expressed in the blood,
plasma, urine, and cerebrospinal fluid—works as a circulating hormone with significant metabolic
functions on different tissues and organs, including anti-inflammatory and anti-oxidative stress
effects [29,32,33]. Thus, the S-Klotho identified in plasma levels, which has been robustly associated
with the α-Klotho gene expression [34], may be a powerful biomarker of biological anti-aging and,
in turn, a promising therapeutic target for the prevention of aged-related disorders.
Sleep and S-Klotho, therefore, share common underlying mechanisms and physiological pathways
through which they are linked to the ageing process in adults, both playing a positive substantial
role in the endocrine [32,35–37] and immune systems [38,39] and, thereby, in oxidative stress [33,40]
and chronic inflammation [29,41,42]—The leading molecular mechanisms behind all age-related
consequences [43–46]. Yet, the available evidence on the relationship between sleep and S-Klotho is
remarkably limited. A previous study by Pákó et al. [47] found reduced levels of S-Klotho in patients
with obstructive sleep apnoea, potentially enhancing the systemic inflammation and endothelial
dysfunction associated with this sleep-related breathing disorder. Similarly, another empirical study
also concluded that sleep deprivation had an adverse effect on S-Klotho responses to exercise testing in
healthy adults [48]. Conversely, the results from a recent study on the role of S-Klotho as a potential
biomarker of stress exposed that unsatisfactory sleep was positively related to increased S-Klotho
levels, although it is worth mentioning that sleep was only subjectively measured [49].
Hence, our study was aimed at elucidating the potential association of objective and subjective
sleep duration and quality—including total sleep time (TST), sleep efficiency (SE), wake after sleep
onset (WASO), and other subjective sleep parameters—with the S-Klotho plasma levels in sedentary
middle-aged adults. In accordance with most but not all available evidence, we hypothesized that
better sleep quantity and quality would be significantly associated with the increased plasma levels
of S-Klotho.
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2. Materials and Methods
2.1. Study Protocol and Participants
A total of 74 sedentary healthy middle-aged volunteers (52.7% women, 53.7 ± 5.1 years old,
26.7 ± 3.8 kg/m2) were recruited for the FIT-AGEING study [50], an exercise-based randomized
controlled trial (clinicaltrial.gov: ID: NCT03334357), approved by the Human Research Ethics
Committee of the “Junta de Andalucía” (0838-N-2017). A detailed explanation of the study methodology
can be found elsewhere [50]. The study was in accordance with ethical principles of the Declaration of
Helsinki. All the participants were given a full explanation of the study, completed a written consent
form, and underwent a complete medical and physical examination prior to their enrolment in the study.
The inclusion criteria were: (i) being aged from 40 to 65 years, (ii) having a body mass index (BMI)
between 18.5 and 35 kg/m2, (iii) having a stable weight in the last three months (weight changes < 3 kg),
(iv) being a non-smoker, and (v) being sedentary (i.e., self-reported <150 min of moderate-intensity
aerobic physical activity throughout the week or <75 min of vigorous-intensity aerobic physical activity
throughout the week). The exclusion criteria were: (i) having some acute or chronic illness, (ii) taking
some medication, and (iii) being pregnant.
2.2. Measurements
2.2.1. Anthropometry and Body Composition
Body weight and height were measured using an electronic scale and stadiometer (model 799,
Electronic Column Scale, Hamburg, Germany). BMI was calculated as weight (kg)/height2 (m2) [51].
A dual-energy X-ray absorptiometry scanner (Hologic, Inc., Bedford, MA, USA) was used to
determine the fat mass and lean mass. The fat mass index (FMI) and lean mass index (LMI) were
calculated as fat mass (kg)/Height2 (m2), and lean mass (kg)/Height2 (m2), respectively.
2.2.2. Sleep Quantity and Quality
The objective characteristics of sleep-wake patterns were assessed with a wrist-worn accelerometer
(ActiGraph GT3X+, Pensacola, FL, USA) continuously 24 h a day for seven consecutive days [50].
The participants received detailed instructions to wear the accelerometer on the non-dominant wrist
and to remove it during water activities. They were provided with a seven-day sleep diary to
record bed-time, wake up time, and the time they removed the device each day. The accelerometer
was initialized to store raw accelerations at a sampling frequency of 100 Hz [52]. The data were
processed using ActiLife software (version 6.13.3, ActiGraph, Pensacola, FL, USA). The GT3X+ files
were subsequently converted to 1 s epoch csv files containing x, y, and z vectors to facilitate raw
data processing. These files were processed in R (version 3.1.2, https://www.cran.r-project.org/)
using GGIR package (version 1.5-12, https://cran.r-project.org/web/packages/GGIR/). The signal
processing included: (i) auto-calibration using local gravity as a reference [53], (ii) the detection of
sustained abnormal high accelerations, (iii) the detection of non-wear time, (iv) the calculation of
the Euclidean Norm Minus One (ENMO), (v) the calculation of waking and sleeping time by an
automatized algorithm [54], and (vi) the imputation of abnormal high values and detected non-wear
time. The variables analyzed from actigraphy recordings were WASO (the sum of wake times from
sleep onset to the final awakening), TST (total amount of time spent in bed minus sleep onset latency),
and SE (percentage of sleep time over the bedtime) [55]. Adherence was defined as ≥ 16 h/day of wear
time for at least four of seven possible days of wear (including at least one weekend day).
The subjective sleep quantity and quality were measured by the Pittsburgh sleep quality index
(PSQI) scale [56]. The PSQI contains 19 self-rated questions for scoring, combined into seven
components, each of them with a range of 0–3 points: (i) subjective sleep quality, (ii) sleep latency,
(iii) sleep duration, (iv) habitual sleep efficiency, (v) sleep disturbances, (vi) the use of sleeping
medication, and (vii) daytime dysfunction. A global PSQI score is obtained by the sum of the seven
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components ranging from 0 to 21. Lower scores denote a healthier sleep quality, whereas a global score
of more than five indicates poor sleep quality.
2.2.3. S-Klotho Plasma Levels
Blood samples were collected from the antecubital vein applying standard techniques after
overnight fasting. The samples were centrifuged and collected at the same time (8:30 a.m.–10 a.m.),
processed in a controlled-temperature room (22 ± 0.5 ◦C), and kept in a −80 ◦C freezer (i.e., 6 months
before the analysis). A solid-phase sandwich enzyme-linked immunosorbent assay (Demeditec, Kiel,
Germany) was used to measure the S-Klotho plasma levels in the ethylenediaminetetraacetic acid
plasma, which was previously validated by both the manufacturer (obtaining a sensitivity analysis
of 6.15 pg/mL) and our own research group (obtaining intra- and inter-assay coefficients of variation
which ranged from ~3% to ~10%). All the participants were requested to abstain from caffeine and/or
drugs, to eat a standardized dinner before sampling, and to refrain from any physical activity of
moderate (24 h before) and/or vigorous intensity (48 h before).
2.3. Statistical Analysis
The normal distribution of the variables was tested through the Shapiro–Wilk test and a visual
check of histograms, Q-Q, and box plots. The descriptive parameters were reported as the mean
and standard deviation. Independent sample T-tests were performed to determine sex differences.
Simple linear regression models were conducted to examine the association of sleep quality
(TST, WASO, SE, and global PSQI score) with the S-Klotho plasma levels. Multiple linear regression
models were also performed to test these associations after adjusting by age, fat mass percentage, FMI,
and LMI.
Statistical Package for the Social Sciences (SPSS, version 23.0, IBM SPSS Statistics, IBM Corporation,
Armonk, NY, USA) was used for the data analyses. P values less than or equal to 0.05 were considered
statistically significant. GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA) was used to
create all the graphical presentations.
3. Results
3.1. Study Participants
The study participants’ characteristics can be found in Table 1. Significant differences between
sex were observed in height, weight, BMI, fat mass percentage, LMI, TST, WASO, SE, subjective sleep
quality (PSQI component), and habitual sleep efficiency (PSQI component) (all p < 0.033). A poor
subjective sleep quality (global PSQI score > 5) was identified in 40.3% of the population.
Table 1. Descriptive characteristics.
Outcome N All N Men N Women
Age (years) 74 53.66 (5.14) 35 54.39 (5.27) 39 53.01 (5.00)
Geographical origin of the population (n/%) 74 35 39
Spain 74 (100.0) 35 (100.0) 39 (100.0)
Place of residence (n/%) 74 35 39
Urban 63 (85.1) 30 (84.7) 33 (84.6)
Rural 11 (14.9) 5 (15.3) 6 (15.4)
Socio-professional category (n/%) 74 35 39
Technicians and professional intellectual scientists 1 (1.35) 0 (0.00) 1 (2.56)
Technicians and associate professionals 3 (4.05) 1 (2.86) 2 (5.13)
Service and sales workers 4 (5.41) 0 (0.00) 4 (10.26)
Skilled agricultural, forestry and fishery workers 43 (58.11) 23 (65.71) 20 (51.28)
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Table 1. Cont.
Outcome N All N Men N Women
Unemployed 2 (2.70) 2 (5.71) 0 (0.00)
Elementary occupations 16 (21.62) 6 (17.14) 10 (25.64)
Others 5 (6.76) 3 (8.58) 2 (5.13)
S-Klotho plasma levels (pg/mL) 73 775.3 (363.7) 34 814.1 (452.2) 39 741.4 (265.6)
Antropometry and Body composition
Height (cm) 74 167.8 (9.81) 35 175.8 (6.48) 39 160.7 (6.10) *
Weight (kg) 74 75.73 (14.98) 35 87.38 (10.95) 39 65.28 (9.32) *
Body mass index (kg/m2) 74 26.72 (3.76) 35 28.32 (3.61) 39 25.27 (3.31) *
Fat mass (%) 74 39.90 (9.06) 35 34.75 (7.99) 39 44.52 (7.36) *
Fat mass index (kg/m2) 74 10.75 (3.13) 35 10.03 (3.23) 39 11.39 (2.93)
Lean mass index (kg/m2) 74 15.21 (2.88) 35 17.49 (2.02) 39 13.17 (1.80) *
Sleep quantity and quality
Objective sleep quantity and quality
Total sleep time (min) 71 359.9 (48.85) 34 340.1 (47.72) 37 378.1 (42.88) *
Wake after sleep onset (min) 71 63.90 (27.44) 34 71.28 (32.70) 37 57.12 (19.63) *
Sleep efficiency (%) 71 85.01 (6.29) 34 82.89 (7.41) 37 86.96 (4.28) *
Subjective sleep quantity and quality
Subjective sleep quality 67 1.13 (0.82) 31 0.84 (0.78) 36 1.39 (0.77) *
Sleep latency 67 1.07 (0.86) 31 1.03 (0.88) 36 1.11 (0.85)
Sleep duration 67 0.99 (0.77) 31 0.97 (0.66) 36 1.00 (0.86)
Habitual sleep efficiency 67 0.60 (0.95) 31 0.32 (0.75) 36 0.83 (1.06) *
Sleep disturbances 67 1.13 (0.42) 31 1.03 (0.41) 36 1.22 (0.42)
Use of sleeping medication 67 0.31 (0.76) 31 0.19 (0.60) 36 0.42 (0.87)
Daytime dysfunction 67 0.37 (0.55) 31 0.39 (0.50) 36 0.36 (0.59)
Global PSQI score 67 5.61 (3.47) 31 4.77 (3.15) 36 6.33 (3.62)
Data are presented as means (standard deviation). * Significant differences between sexes obtained from an
independent sample t-Test (p < 0.05). S-Klotho = Secreted Klotho; PSQI = Pittsburgh Sleep Quality Index.
3.2. Association between Objective Sleep Quantity and Quality and S-Klotho
Figure 1 shows the association of objective sleep quantity and quality with the S-Klotho plasma
levels. TST, WASO, and SE were not associated with the S-Klotho plasma levels (all p > 0.05,
Figure 1A–C).
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Table 2 shows the relationship of objective sleep quantity and quality with the S-Klotho plasma
levels adjusted by age, fat mass percentage, FMI, and LMI in the statistical models. An association
of TST, WASO, and SE with S-Klotho appeared after including age, fat mass percentage, and LMI
as covariates.
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Table 2. Association of objective sleep quantity and quality with the secreted Klotho plasma levels
(Model 0) adjusted by age (Model 1), total fat mass percentage (Model 2), fat mass index (Model 3),
and lean mass index (Model 4).
Model
All Men Women
β R2 p β R2 p β R2 p
Total sleep time
Model 0 −0.111 0.012 0.362 −0.094 0.009 0.601 −0.065 0.004 0.702
Model 1 −0.057 0.482 <0.001 −0.033 0.657 <0.001 0.102 0.419 <0.001
Model 2 0.031 0.106 0.023 −0.029 0.060 0.393 0.065 0.251 0.007
Model 3 −0.094 0.015 0.597 −0.106 0.010 0.857 −0.038 0.043 0.476
Model 4 0.137 0.356 <0.001 −0.069 0.722 <0.001 0.162 0.549 <0.001
Wake after sleep onset
Model 0 0.100 0.010 0.409 0.071 0.005 0.693 0.098 0.010 0.566
Model 1 0.108 0.491 <0.001 −0.028 0.656 <0.001 0.156 0.433 <0.001
Model 2 −0.012 0.106 0.024 −0.007 0.060 0.398 0.036 0.248 0.008
Model 3 0.083 0.014 0.633 0.082 0.006 0.912 0.083 0.048 0.433
Model 4 −0.054 0.343 <0.001 0.002 0.717 <0.001 0.036 0.526 <0.001
Sleep efficiency
Model 0 −0.099 0.010 0.413 −0.062 0.004 0.732 −0.103 0.011 0.544
Model 1 −0.107 0.491 <0.001 0.013 0.656 <0.001 −0.108 0.421 <0.001
Model 2 0.035 0.106 0.023 0.020 0.060 0.396 −0.011 0.247 0.008
Model 3 −0.081 0.013 0.644 −0.073 0.005 0.932 −0.080 0.048 0.436
Model 4 0.093 0.348 <0.001 −0.004 0.717 <0.001 0.000 0.525 <0.001
β (standardized regression coefficient), R2, and p-value of simple and multiple-regression analysis. Significant p
values (<0.05) are in bold.
3.3. Association between Subjective Sleep Quantity and Quality and S-Klotho
Figure 2 shows the association of subjective sleep quantity and quality (components and global
PSQI score) with the S-Klotho plasma levels. An inverse relationship was observed between the global
PSQI score and the S-Klotho plasma levels (β = −0.438, R2 = 0.192, p < 0.001, Figure 2H), meaning
that a higher subjective sleep quality was significantly related to increased S-Klotho plasma levels.
Furthermore, our results showed the inverse associations of subjective sleep quality, sleep latency,
habitual sleep efficiency, and sleep disturbance PSQI components with the S-Klotho plasma levels
(β = −0.368, R2 = 0.135, p = 0.002, Figure 2A; β = −0.519, R2 = 0.269, p < 0.001, Figure 2B; β = −0.277,
R2 = 0.077, p = 0.024, Figure 2D; β = −0.407, R2 = 0.165, p = 0.001, Figure 2E, respectively). Therefore,
better sleep quality and efficiency, shorter sleep latency, and lower levels of sleep disturbances were all
related to higher plasma levels of S-Klotho. We did not observe any significant associations between
sleep duration, the use of sleeping medication, and daytime dysfunction with the S-Klotho plasma
levels (all p > 0.05, Figure 2C,F,G).
Table 3 shows the relationship of subjective sleep quantity and quality (components and global
PSQI score) with the S-Klotho plasma levels adjusted by age, fat mass percentage, FMI, and LMI in
the statistical models. All of the above-mentioned findings persisted once age, fat mass percentage,
FMI, and LMI were included in the statistical models. Furthermore, the associations between sleep
duration, the use of sleeping medication, and daytime dysfunction with the S-Klotho plasma levels
appeared after adjusting by age, fat mass percentage, and LMI.
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Table 3. Association of subjective sleep quantity and quality (components and global PSQI score)
with the secreted Klotho plasma levels (Model 0) adjusted by age (Model 1), total fat mass percentage
(Model 2), fat mass index (Model 3), and lean mass index (Model 4).
Model
All Men Women
β R2 p β R2 p β R2 p
Subjective sleep quality
Model 0 −0.368 0.135 0.002 −0.351 0.123 0.057 −0.412 0.170 0.013
Model 1 −0.275 0.573 <0.001 −0.146 0.633 <0.001 −0.318 0.599 <0.001
Model 2 −0.250 0.191 0.001 −0.302 0.166 0.087 −0.188 0.399 <0.001
Model 3 −0.349 0.139 0.009 −0.354 0.124 0.168 −0.334 0.224 0.015
Model 4 −0.131 0.332 <0.001 −0.063 0.696 <0.001 −0.195 0.535 <0.001
Sleep latency
Model 0 −0.519 0.269 <0.001 −0.565 0.319 0.001 −0.483 0.234 0.003
Model 1 −0.350 0.611 <0.001 −0.354 0.726 <0.001 −0.319 0.594 <0.001
Model 2 −0.451 0.331 <0.001 −0.528 0.336 0.004 −0.335 0.473 <0.001
Model 3 −0.505 0.275 <0.001 −0.572 0.322 0.005 −0.432 0.304 0.003
Model 4 −0.384 0.453 <0.001 −0.196 0.722 <0.001 −0.295 0.581 <0.001
Sleep duration
Model 0 −0.140 0.020 0.261 −0.153 0.023 0.420 −0.147 0.021 0.394
Model 1 −0.101 0.509 <0.001 −0.091 0.622 <0.001 −0.113 0.512 <0.001
Model 2 −0.119 0.156 0.005 −0.107 0.091 0.277 −0.163 0.397 <0.001
Model 3 −0.136 0.046 0.228 −0.152 0.023 0.726 −0.162 0.150 0.068
Model 4 −0.095 0.328 <0.001 0.015 0.693 <0.001 −0.128 0.518 <0.001
Habitual sleep efficiency
Model 0 −0.277 0.077 0.024 −0.443 0.197 0.014 −0.140 0.020 0.414
Model 1 −0.209 0.542 <0.001 −0.252 0.673 <0.001 −0.087 0.507 <0.001
Model 2 −0.215 0.186 0.002 −0.424 0.258 0.018 −0.123 0.385 <0.001
Model 3 −0.282 0.107 0.028 −0.451 0.202 0.048 −0.177 0.155 0.062
Model 4 −0.065 0.322 <0.001 −0.064 0.696 <0.001 0.010 0.502 <0.001
Sleep disturbances
Model 0 −0.407 0.165 0.001 −0.445 0.198 0.014 −0.376 0.141 0.024
Model 1 −0.125 0.511 <0.001 −0.070 0.617 <0.001 −0.057 0.502 <0.001
Model 2 −0.335 0.247 <0.001 −0.408 0.241 0.024 −0.301 0.459 <0.001
Model 3 −0.400 0.187 0.001 −0.445 0.198 0.051 −0.396 0.280 0.004
Model 4 −0.207 0.354 <0.001 −0.131 0.707 <0.001 −0.129 0.516 <0.001
Use of sleeping medication
Model 0 −0.150 0.023 0.229 −0.378 0.143 0.039 0.062 0.004 0.720
Model 1 −0.158 0.523 <0.001 −0.228 0.663 <0.001 −0.010 0.500 <0.001
Model 2 −0.088 0.149 0.006 −0.323 0.175 0.074 0.069 0.375 <0.001
Model 3 −0.143 0.048 0.214 −0.378 0.143 0.125 0.051 0.127 0.107
Model 4 0.009 0.319 <0.001 0.103 0.700 <0.001 0.135 0.520 <0.001
Daytime dysfunction
Model 0 −0.211 0.045 0.089 −0.335 0.112 0.071 −0.102 0.010 0.555
Model 1 −0.137 0.517 <0.001 −0.234 0.668 <0.001 −0.044 0.502 <0.001
Model 2 −0.188 0.177 0.002 −0.381 0.222 0.034 0.074 0.375 <0.001
Model 3 −0.206 0.070 0.103 −0.353 0.121 0.176 −0.025 0.125 0.111
Model 4 −0.161 0.344 <0.001 −0.169 0.720 <0.001 0.007 0.502 <0.001
Global PSQI score
Model 0 −0.438 0.192 <0.001 −0.563 0.317 0.001 −0.323 0.104 0.055
Model 1 −0.304 0.587 <0.001 −0.323 0.704 <0.001 −0.209 0.542 <0.001
Model 2 −0.355 0.255 <0.001 −0.525 0.339 0.004 −0.197 0.407 <0.001
Model 3 −0.423 0.204 0.001 −0.563 0.317 0.006 −0.292 0.208 0.021
Model 4 −0.236 0.364 <0.001 −0.131 0.704 <0.001 −0.118 0.515 <0.001
β (standardized regression coefficient), R2, and p-value of simple and multiple-regression analysis. Significant p
values (<0.05) are in bold. PSQI = Pittsburgh Sleep Quality Index.
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4. Discussion
Our study sought to elucidate the relationship between sleep quantity and quality and the S-Klotho
plasma levels in sedentary middle-aged adults. As we expected, the results from the current study
indicated that objective sleep quantity and quality parameters (TST, WASO, and SE) were significantly
associated with the S-Klotho plasma levels when age, fat mass percentage, and LMI were considered
as covariates. Furthermore, we observed that better subjective sleep quality (measured by the global
PSQI score) was related to higher levels of S-Klotho plasma levels in sedentary middle-aged adults.
These results therefore have important clinical implications, as improving sleep quantity and quality
could be considered a novel anti-aging therapeutic approach via increasing the S-klotho plasma levels.
Sleep quantity and quality represent a cornerstone in the maintenance of health and well-being,
particularly during the senescence process and thus in the prevention of numerous degenerative chronic
diseases [57–62]. Poor sleep quality and both short and long sleep duration have been previously
associated with a lifespan reduction due to the associated deleterious effects on health and the higher
risk of several diseases [18,63]. Sleep and S-Klotho have both been widely shown to be related to
the ageing process [29,32,33,35–42], sharing underlying mechanisms and physiological pathways
such as endocrine functions and metabolism, immune response and, consequently, oxidative stress
and chronic inflammation. However, the relationship between these two aged-related factors still
remains unclear. According to our results, better subjective sleep quality was positively related to
enhanced levels of S-Klotho. A previous study by Nakanishi et al. [49], however, conversely found
that subjective sleep dissatisfaction was related to higher levels of this anti-aging protein. This inverse
association could be explained by a compensatory mechanism triggered to counteract the inflammatory
stress-derived environment produced by sleep deprivation [49]. Nevertheless, as previously mentioned,
it is also noteworthy that sleep in the study by Nakanishi et al. [49] was solely measured using one
item on “relaxation from sleep”.
Regarding objective sleep and in accordance with previous findings [47,48], our results indicated
that shorter sleep was related to reduced S-Klotho plasma levels after adjusting by fat mass percentage
and LMI. These results are in accordance with previous findings [47,48], where sleep deprivation
and obstructive sleep apnea—which causes short sleep and sleep fragmentation due to the repetitive
collapse of the upper airway during sleep—were related to lower levels of the anti-aging protein.
According to the evidence, the short sleep and chronic intermittent hypoxia caused by sleep apnea
are both closely related to energy imbalance and obesity [13,14], adverse hormonal changes [15],
gut microbiota alterations [16], vitamin D deficiency [17], and thus systemic inflammation and oxidative
stress [40–42,47]. These physiological consequences, in turn, may lead to reduced S-Klotho levels,
as it is known that factors such as obesity, vitamin D deficiency, and systemic inflammation suppress
renal klotho synthesis [47,64,65]. Subsequently, a reduction in the S-Klotho expression may result
in endothelial dysfunction, excessive aldosterone production, hypertension, renal structure damage,
and functional decline, exacerbating therefore the increased systemic inflammation and oxidative
stress found in sleep disturbances such as obstructive sleep apnea and/or sleep curtailment [47,66,67].
To the best of our knowledge, this is the first study describing the relationship between sleep
quantity and quality and the S-Klotho plasma levels in healthy sedentary middle-aged adults.
Our results therefore have robust clinical and research implications, supporting the association of better
sleep quantity and quality with increased plasma levels of S-Klotho. Considering the increasingly
high prevalence of sleep disturbances and its association with age-related disorders [68–74], promising
anti-aging interventions should consider sleep as a modifiable factor for healthy aging. In this regard,
the measurement of S-Klotho plasma levels could be used as a marker of a healthier and anti-aging sleep.
However, our study has some limitations that need to be addressed in future studies.
Firstly, the cross-sectional study design used does not allow the identification of any causal association
between the variables included, so well-designed longitudinal studies are needed to robustly analyze
and establish causal relationships between sleep and S-Klotho. Secondly, the participants included in
our sample were healthy sedentary middle-aged adults, such that these findings cannot be extrapolated
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to other individuals with different biological characteristics. Finally, although we used accelerometry as
an objective tool to assess sleep quantity and quality, future studies should include polysomnography,
which is the gold-standard method to appropriately assess not only sleep duration and efficiency but
also other significant sleep outcomes, such as sleep architecture.
5. Conclusions
In accordance with our findings, an increased subjective sleep quality was associated with higher
S-Klotho plasma levels in sedentary middle-aged adults. Moreover, TST, WASO, and SE were positively
related to the S-Klotho plasma levels after controlling for confounders. Therefore, improving sleep
quantity and quality could be considered an anti-aging therapeutic approach for the prevention,
slowing, and even reversal of the physiological decline and degenerative pathologies that are certainly
related to the aging process.
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